Resource Summary

Clinical Question:
What are the benefits and risks of dabigatran (Pradax) (a direct thrombin inhibitor)^ compared to warfarin^ in patients with atrial fibrillation?

Bottom-line:
Dabigatran offers some advantages over warfarin (example -0.6 percent/year fewer strokes)^ but benefits decline as warfarin time in INR range improves. If using Dabigatran 150mg bid is generally recommended.


*** Original Documents can be found and downloaded using the link provided below ***

https://www.acfp.ca/tools-for-practice/

Publication Date: 2015-2-9
Last Updated on PCR: 2017-03-31 15:17:24